Abstract
In 2010, it was estimated that 217, 730 men in the United States were diagnosed with prostate cancer (Jemal et al. CA Cancer J Clin 60(5):277–300, 2010). Although serum prostate-specific antigen (PSA) testing and digital rectal exams (DRE) help identify men at risk for prostate cancer, the gold standard for diagnosis is currently biopsy of the prostate. With recent trends toward PSA screening, there has been an increase in the number of men being diagnosed with prostate cancer and the number of men undergoing biopsy of the prostate. It has been estimated that as many as 800,000 biopsies of the prostate are performed in the United States each year making it one of the most common office procedures for urologists (Halpern and Strup AJR Am J Roentgenol 174:623–27, 2000).